Tenax Therapeutics (NASDAQ:TENX – Get Free Report) and Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.
Institutional and Insider Ownership
1.7% of Tenax Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 3.1% of Tenax Therapeutics shares are owned by company insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Tenax Therapeutics and Gyre Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tenax Therapeutics | 1 | 0 | 3 | 0 | 2.50 |
| Gyre Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Profitability
This table compares Tenax Therapeutics and Gyre Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tenax Therapeutics | N/A | -43.24% | -41.52% |
| Gyre Therapeutics | 6.20% | 9.50% | 7.87% |
Risk and Volatility
Tenax Therapeutics has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500.
Earnings & Valuation
This table compares Tenax Therapeutics and Gyre Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tenax Therapeutics | N/A | N/A | -$17.60 million | ($1.13) | -10.48 |
| Gyre Therapeutics | $105.76 million | 7.13 | $12.09 million | $0.03 | 261.00 |
Gyre Therapeutics has higher revenue and earnings than Tenax Therapeutics. Tenax Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Gyre Therapeutics beats Tenax Therapeutics on 11 of the 12 factors compared between the two stocks.
About Tenax Therapeutics
Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.
About Gyre Therapeutics
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
